MicroRNAs and therapeutic potentials in acute and chronic cardiac disease

Rui Song1, Lubo Zhang1

  • 1Lawrence D. Longo, MD Center for Perinatal Biology, Department of Basic Sciences, Loma Linda University School of Medicine, Loma Linda, CA, USA.

Drug Discovery Today
|September 14, 2024
PubMed

Insights

MicroRNAs (miRNAs) are key regulators in heart disease. This review details their role in acute myocardial infarction and chronic heart failure, highlighting distinct profiles and therapeutic potential.

Area of Science:

  • Molecular Biology
  • Cardiology
  • Biochemistry

Background:

  • MicroRNAs (miRNAs) are small regulatory RNAs involved in cellular processes.
  • Cardiac disorders, including myocardial infarction and heart failure, are associated with altered miRNA expression.
  • Understanding miRNA dysregulation is crucial for developing novel therapeutic strategies.

Purpose of the Study:

  • To review the role of miRNAs in acute myocardial infarction and chronic heart failure.
  • To discuss the differences in miRNA profiles between these cardiac conditions.
  • To explore the challenges and progress in miRNA-based therapeutic strategies for heart diseases.

Main Methods:

  • Literature review of studies investigating miRNA involvement in cardiac disorders.
  • Analysis of miRNA expression patterns in acute myocardial infarction and chronic heart failure.
  • Evaluation of current miRNA-based treatment strategies and their clinical translation.

Main Results:

  • miRNAs are significantly altered in both acute myocardial infarction and chronic heart failure, contributing to cardiac injury and remodeling.
  • Distinct miRNA signatures are observed between acute ischemic injury and progressive heart failure.
  • Variability in miRNA profiles and challenges in delivery hinder the translation of preclinical findings to clinical applications.

Conclusions:

  • Distinct miRNA signatures offer potential for stage-specific therapeutic interventions in cardiac diseases.
  • Further research is needed to overcome challenges in miRNA delivery and clinical translation.
  • Targeting miRNAs holds promise for developing novel treatments for acute and chronic heart conditions.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
398
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
543
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K